Jan P Dutz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8633917/publications.pdf

Version: 2024-02-01

123 5,642 39 71
papers citations h-index g-index

126 126 126 7748
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 480-489.	0.9	671
2	Psoriasis and Pustular Dermatitis Triggered by TNF- \hat{l}_{\pm} Inhibitors in Patients With Rheumatologic Conditions. Archives of Dermatology, 2007, 143, 223-31.	1.4	291
3	New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy, 2007, 20, 160-174.	1.7	234
4	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
5	Cutting Edge: Signaling Lymphocytic Activation Molecule-Associated Protein Controls NKT Cell Functions. Journal of Immunology, 2005, 174, 3153-3157.	0.8	160
6	Cutting Edge: Defective NK Cell Activation in X-Linked Lymphoproliferative Disease. Journal of Immunology, 2000, 165, 3549-3553.	0.8	146
7	Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. Journal of the American Academy of Dermatology, 2014, 71, 941-947.	1.2	144
8	Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME Journal, 2016, 10, 321-332.	9.8	140
9	Phagocytosis of Apoptotic Cells by Macrophages From NOD Mice Is Reduced. Diabetes, 2002, 51, 2481-2488.	0.6	134
10	Expansion of Antigen-Specific Regulatory T Cells with the Topical Vitamin D Analog Calcipotriol. Journal of Immunology, 2009, 182, 6071-6078.	0.8	127
11	Decidual NK Cells Alter In Vitro First Trimester Extravillous Cytotrophoblast Migration: A Role for IFN-Î ³ . Journal of Immunology, 2006, 177, 8522-8530.	0.8	122
12	Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice. Diabetologia, 2010, 53, 741-748.	6.3	114
13	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. Journal of Rheumatology, 2015, 42, 1767-1780.	2.0	113
14	Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. Journal of Clinical Investigation, 2003, 111, 217-223.	8.2	108
15	Pathophysiology of Cutaneous Lupus Erythematosus. Clinical Reviews in Allergy and Immunology, 2007, 33, 85-106.	6.5	102
16	In Situ \hat{I}^2 Cell Death Promotes Priming of Diabetogenic CD8 T Lymphocytes. Journal of Immunology, 2002, 168, 1466-1472.	0.8	96
17	Regulation of Autoimmune Diabetes by Complete Freund's Adjuvant Is Mediated by NK Cells. Journal of Immunology, 2004, 172, 937-942.	0.8	96
18	Molecular Markers of Early-Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2012, 132, 1698-1706.	0.7	88

#	Article	IF	CITATIONS
19	IMMUNOSUPPRESSIVE AGENTS IN DERMATOLOGY. Dermatologic Clinics, 1998, 16, 235-251.	1.7	86
20	Skin Exposure to Narrow Band Ultraviolet (UVB) Light Modulates the Human Intestinal Microbiome. Frontiers in Microbiology, 2019, 10, 2410.	3.5	84
21	Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin. PLoS ONE, 2012, 7, e51040.	2.5	83
22	Tolerance Induction by Transcutaneous Immunization through Ultraviolet-Irradiated Skin Is Transferable through CD4+CD25+ T Regulatory Cells and Is Dependent on Host-Derived IL-10. Journal of Immunology, 2006, 176, 2635-2644.	0.8	77
23	Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood, 2001, 97, 95-100.	1.4	73
24	Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood, 2010, 116, 5748-5751.	1.4	70
25	TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes. Journal of Immunology, 2010, 184, 5645-5653.	0.8	70
26	Identification of Autoantigen Epitopes inÂAlopecia Areata. Journal of Investigative Dermatology, 2016, 136, 1617-1626.	0.7	69
27	Optimization of epicutaneous immunization for the induction of CTL. Vaccine, 2003, 21, 2890-2899.	3.8	65
28	Better Influenza Vaccines for Older People: What Will It Take?. Journal of Infectious Diseases, 2008, 198, 632-634.	4.0	61
29	Cyclosporine Treatment of Drug-Induced Hypersensitivity Syndrome. JAMA Dermatology, 2016, 152, 1254.	4.1	59
30	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. American Journal of Medicine, 2016, 129, 1221-1225.	1.5	56
31	Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. Oncotarget, 2014, 5, 4418-4425.	1.8	55
32	Psoriasis and Smoking. Journal of Cutaneous Medicine and Surgery, 2016, 20, 221-227.	1.2	49
33	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. Journal of the American Academy of Dermatology, 2017, 77, 261-267.	1.2	48
34	Metaâ€Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials. Arthritis Care and Research, 2015, 67, 754-764.	3.4	46
35	Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL. Journal of Investigative Dermatology, 2004, 122, 1042-1049.	0.7	45
36	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. Journal of Rheumatology, 2018, 45, 378-384.	2.0	45

#	Article	lF	CITATIONS
37	Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine, 2004, 22, 1985-1991.	3.8	43
38	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1426-1439.	2.0	43
39	The pathophysiology of photosensitivity in lupus erythematosus. Photodermatology Photoimmunology and Photomedicine, 2001, 17, 95-113.	1.5	40
40	Targeting the IL-17/IFN- \hat{l}^3 axis as a potential new clinical therapy for type 1 diabetes. Clinical Immunology, 2014, 154, 84-89.	3.2	40
41	Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine, 2009, 27, 5791-5799.	3.8	39
42	Mycophenolate Mofetil (CellCept \hat{A}^{\otimes}) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. Journal of Cutaneous Medicine and Surgery, 2003, 7, 193-197.	1.2	38
43	Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Diabetologia, 2011, 54, 1407-1416.	6.3	38
44	Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. Burns, 2018, 44, 807-815.	1.9	38
45	An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. Journal of the American Academy of Dermatology, 2021, 84, 1652-1666.	1.2	38
46	Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. Current Opinion in Rheumatology, 1997, 9, 400-409.	4.3	35
47	Psychiatric Disorders in Patients with Immune-Mediated Inflammatory Diseases: Prevalence, Association with Disease Activity, and Overall Patient Well-being. Journal of rheumatology Supplement, The, 2011, 88, 31-35.	2.2	35
48	Type 1 IFNâ€induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Experimental Dermatology, 2012, 21, 417-419.	2.9	35
49	IgG4â€related disease and lymphocyteâ€variant hypereosinophilic syndrome: A comparative case series. European Journal of Haematology, 2017, 98, 378-387.	2.2	35
50	IFN-Â-mediated extravillous trophoblast outgrowth inhibition in first trimester explant culture: a role for insulin-like growth factors. Molecular Human Reproduction, 2008, 14, 281-289.	2.8	31
51	Think beyond the Skin. Journal of Cutaneous Medicine and Surgery, 2015, 19, 22-27.	1.2	31
52	Collagen Triple Helix Repeat Containing 1 Promotes Melanoma Cell Adhesion and Survival. Journal of Cutaneous Medicine and Surgery, 2011, 15, 103-110.	1.2	30
53	A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and a nonself class I MHC protein. Molecular Immunology, 1994, 31, 967-975.	2.2	29
54	Murine models of cutaneous involvement in lupus erythematosus. Autoimmunity Reviews, 2009, 8, 484-487.	5.8	28

#	Article	IF	Citations
55	Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 1481-1488.	3.4	28
56	Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy, 2021, 11, 1053-1064.	3.0	28
57	Cigarette Smoking and Response to Antimalarials in Cutaneous Lupus Erythematosus Patients: Evolution of a Dogma. Journal of Investigative Dermatology, 2011, 131, 1968-1970.	0.7	27
58	The Immunopathology of Cutaneous Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2014, 40, 455-474.	1.9	26
59	Development and Validation of an Artificial Mechanical Skin Model for the Study of Interactions between Skin and Microneedles. Macromolecular Materials and Engineering, 2016, 301, 306-314.	3.6	25
60	Mycophenolate Mofetil (CellCept�) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. Journal of Cutaneous Medicine and Surgery, 2003, 7, 193-197.	1.2	24
61	Topical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine. Journal of Investigative Dermatology, 2008, 128, 2204-2210.	0.7	24
62	Fas (CD95)-independent regulation of immune responses by antigen-specific CD4â€"CD8+ T cells. International Immunology, 1996, 8, 675-681.	4.0	22
63	Islet Allograft Rejection Is Independent of Toll-Like Receptor Signaling in Mice. Transplantation, 2009, 88, 1075-1080.	1.0	22
64	Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum. Lancet, The, 2021, 398, 621.	13.7	22
65	Effects of cognate peptides on cytolytic and proliferative activities of cloned cytotoxic T lymphocytes. International Immunology, 1992, 4, 571-580.	4.0	21
66	Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. International Immunology, 2009, 21, 757-767.	4.0	21
67	Crusted Scabies in Association with Human T-Cell Lymphotropic Virus 1. Journal of Cutaneous Medicine and Surgery, 1999, 3, 148-152.	1.2	20
68	Topical TLR9 agonists induce more efficient crossâ€presentation of injected protein antigen than parenteral TLR9 agonists do. European Journal of Immunology, 2007, 37, 2242-2256.	2.9	20
69	Quality of Life in Patients with Immune-Mediated Inflammatory Diseases. Journal of rheumatology Supplement, The, 2011, 88, 7-19.	2.2	20
70	Tolerogenic effect of mouse fibroblasts on dendritic cells. Immunology, 2016, 148, 22-33.	4.4	19
71	Infection risk of dermatologic therapeutics during the COVIDâ€19 pandemic: an evidenceâ€based recalibration. International Journal of Dermatology, 2020, 59, 1043-1056.	1.0	19
72	A Novel T Cell Receptor Transgenic Animal Model of Seborrheic Dermatitis-Like Skin Disease. Journal of Investigative Dermatology, 2005, 124, 151-159.	0.7	18

#	Article	IF	CITATIONS
73	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. Journal of Rheumatology, 2017, 44, 519-534.	2.0	18
74	Treg gene signatures predict and measure type 1 diabetes trajectory. JCI Insight, 2019, 4, .	5.0	18
75	Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology, 2004, 16, 1657-1662.	4.0	17
76	T-Cell-Mediated Injury to Keratinocytes: Insights from Animal Models of the Lichenoid Tissue Reaction. Journal of Investigative Dermatology, 2009, 129, 309-314.	0.7	17
77	Atrophie Blanche. Advances in Skin and Wound Care, 2014, 27, 518-524.	1.0	17
78	Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Reports, 2022, 20, 61-64.	0.8	14
79	Tumor necrosis factor-a inhibition and palmoplantar pustulosis: Janus-faced therapy?. Journal of Rheumatology, 2007, 34, 247-9.	2.0	14
80	Pegylated interferon alpha 2a is an effective and wellâ€ŧolerated treatment option for lymphocyteâ€variant hypereosinophilic syndrome. British Journal of Haematology, 2020, 188, e68-e72.	2.5	13
81	Treatment of Atypical Nevi With Imiquimod 5% Cream. Archives of Dermatology, 2007, 143, 379-85.	1.4	12
82	Usefulness of Interferon- \hat{I}^3 Release Assays in the Diagnosis of Erythema Induratum. Archives of Dermatology, 2011, 147, 949.	1.4	12
83	Topical CpG Adjuvantation of a Protein-Based Vaccine Induces Protective Immunity to Listeria monocytogenes. Vaccine Journal, 2014, 21, 329-339.	3.1	12
84	<i>HLA-B*58:01</i> Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinolâ€"A Canadian Missed Opportunity. Journal of Cutaneous Medicine and Surgery, 2019, 23, 595-601.	1.2	12
85	Immunosuppressive Agents in Skin Disorders. BioDrugs, 1996, 5, 268-293.	0.7	11
86	D-Dimer Levels as a Marker of Cutaneous Disease Activity. JAMA Dermatology, 2014, 150, 880.	4.1	9
87	New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus. JAAD Case Reports, 2019, 5, 682-685.	0.8	9
88	Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid. JAAD Case Reports, 2019, 5, 660-662.	0.8	8
89	A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. International Journal of Dermatology, 1998, 37, 51-53.	1.0	8
90	Clinical and genetic registries in psoriatic disease. Journal of Rheumatology, 2008, 35, 1458-63.	2.0	8

#	Article	IF	CITATIONS
91	Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens. Biology of Blood and Marrow Transplantation, 2012, 18, 546-556.	2.0	7
92	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leukemia and Lymphoma, 2017, 58, 711-714.	1.3	7
93	Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. Allergy, Asthma and Clinical Immunology, 2017, 13, 38.	2.0	7
94	Topical Adjuvant Application during Subcutaneous Vaccination Promotes Resident Memory T Cell Generation. Journal of Immunology, 2019, 203, 2443-2450.	0.8	7
95	Skin immune responses to peptide and protein antigen are TLR4 independent. Cellular Immunology, 2003, 226, 116-123.	3.0	6
96	lxekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-NaÃ-ve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H. Rheumatology and Therapy, 2022, 9, 109-125.	2.3	6
97	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. International Journal of Women's Dermatology, 2016, 2, 44-45.	2.0	5
98	Case Series: A Kindred With Eruptive Vellus Hair Cysts and Systemic Features. Journal of Cutaneous Medicine and Surgery, 2017, 21, 564-567.	1.2	5
99	A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. Immunotherapy Advances, 2022, 2, Itab022.	3.0	5
100	A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 13-16.	0.7	5
101	Psoriasiform Eruptions During Anti–TNF-α Treatment: Psoriasis or Not?—Reply. Archives of Dermatology, 2007, 143, 1589.	1.4	4
102	Amyopathic Dermatomyositis–Related Thrombophilia. JAMA Dermatology, 2015, 151, 559.	4.1	4
103	Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 153-166.	1.4	4
104	Finger pad tophi in a patient with Raynaud phenomenon. JAAD Case Reports, 2017, 3, 45-48.	0.8	4
105	Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report. SAGE Open Medical Case Reports, 2019, 7, 2050313X1985739.	0.3	3
106	Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. Current Treatment Options in Rheumatology, 2020, 6, 406-417.	1.4	3
107	Response to: †Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers. Annals of the Rheumatic Diseases, 2015, 74, e34-e34.	0.9	2
108	Methotrexateâ€"The Value of Case Series for Older Drugs. Journal of Cutaneous Medicine and Surgery, 2018, 22, 537-537.	1,2	2

#	Article	IF	CITATIONS
109	Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 437-438.	2.0	2
110	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265.	3.0	2
111	Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals. Contact Dermatitis, 2020, 82, 170-173.	1.4	1
112	Response to comment on "An evidence-based guide to SARS-Cov-2 vaccination of patients on immunotherapies in dermatology.― Journal of the American Academy of Dermatology, 2021, 85, e91.	1.2	1
113	Cutaneous CpG adjuvant conditioning to enhance vaccine responses. Vaccine, 2022, , .	3.8	1
114	Small plaque psoriasis reâ€visited: A type of psoriasis mediated by a typeâ€l interferon pathway. Experimental Dermatology, 2021, , .	2.9	1
115	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy, 2022, 12, 1073-1089.	3.0	1
116	Sclerotic skin disease: when smooth skin is unwelcome. Expert Review of Dermatology, 2006, 1, 487-492.	0.3	0
117	The Skin as a Site of Initiation of Systemic Autoimmune Disease: New Opportunities for Treatment. Journal of Investigative Dermatology, 2006, 126, 1209-1212.	0.7	0
118	Microbiota Regulates Intestinal Inflammation, Th17 Immunity and Barrier Function in the Non-obese Diabetic Mouse. Canadian Journal of Diabetes, 2012, 36, S60.	0.8	0
119	Dr. Roubille, et al reply. Journal of Rheumatology, 2016, 43, 993-994.	2.0	0
120	CS-36â€Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
121	Prevention of allopurinol-associated adverse cutaneous drug reactions in high-risk patient groups in Canada. Cmaj, 2020, 192, E168-E168.	2.0	0
122	Recurrent sterile abscesses in a case of Xâ€linked neutropenia. Pediatric Dermatology, 2020, 37, 742-744.	0.9	0
123	Development of a Modified Skin Explant Assay to Study Treg Suppression of Th17 Cell Mediated GvHD in the Skin. Blood, 2008, 112, 5434-5434.	1.4	0